Literature DB >> 20430728

Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer.

Bozena Dobrzycka1, Slawomir J Terlikowski, Magdalena Garbowicz, Wieslawa Niklińska, Piotr S Bernaczyk, Jacek Nikliński, Maciej Kinalski, Lech Chyczewski.   

Abstract

The aim of the present study was to characterize the expression pattern of tumor necrosis factor (TNF)-alpha and its receptors (TNF-Rs) in the epithelial ovarian cancer (EOC) and compare these results with the outcome of 126 patients. Presence of TNF-alpha, TNFR-1 and TNFR-2 were studied by Western blotting and immunohistochemistry. The proportion of samples positive for TNF-alpha and TNF-R2 was higher in epithelial ovarian cancer patients than in benign ovarian diseases (p<0.001 and p=0.016, respectively). Immunostaining intensity of TNF-R2 were correlated with tumor stage (p<0.001) and with reduced mean survival time (MST) (p=0.002). The results of the present study suggested that tissue expression of TNF-R2 in epithelial ovarian cancer was correlated with the highest risk of cancer progression. Thus, the clinical value of activated TNF system in epithelial ovarian cancer needs to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20430728     DOI: 10.2478/v10042-008-0117-1

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  10 in total

1.  Interaction between TNFR1 and TNFR2 dominates the clinicopathologic features of human hypopharyneal carcinoma.

Authors:  Xiuru Ma; Xiaoming Li; Xiuying Lu; Lifeng Jia; Hui Li; Qi Song
Journal:  Tumour Biol       Date:  2015-06-27

2.  Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update.

Authors:  Subeka Abraham Gnanadass; Yogamaya Divakar Prabhu; Abilash Valsala Gopalakrishnan
Journal:  Arch Gynecol Obstet       Date:  2021-01-13       Impact factor: 2.344

3.  Diallyl disulfide inhibits TNFα induced CCL2 release through MAPK/ERK and NF-Kappa-B signaling.

Authors:  D Bauer; N Redmon; E Mazzio; E Taka; J S Reuben; A Day; S Sadrud-Din; H Flores-Rozas; K F A Soliman; S Darling-Reed
Journal:  Cytokine       Date:  2015-06-20       Impact factor: 3.861

4.  TNF-R2 in tumor microenvironment as prognostic factor in epithelial ovarian cancer.

Authors:  Rosekeila Simões Nomelini; Luciano Eliziário Borges Júnior; Cid Almeida de Lima; Ana Flávia Carrijo Chiovato; Douglas Côbo Micheli; Beatriz Martins Tavares-Murta; Eddie Fernando Candido Murta
Journal:  Clin Exp Med       Date:  2018-05-25       Impact factor: 3.984

5.  Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.

Authors:  Jacek R Wilczyński; Marek Nowak
Journal:  Exp Suppl       Date:  2022

Review 6.  The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy.

Authors:  Hiroyuki Takahashi; Gumpei Yoshimatsu; Denise Louise Faustman
Journal:  Cells       Date:  2022-06-17       Impact factor: 7.666

7.  A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer.

Authors:  Elizabeth M Poole; I-Min Lee; Paul M Ridker; Julie E Buring; Susan E Hankinson; Shelley S Tworoger
Journal:  Am J Epidemiol       Date:  2013-08-21       Impact factor: 4.897

8.  Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells.

Authors:  Deok-Soo Son; Syeda M Kabir; Yuanlin Dong; Eunsook Lee; Samuel E Adunyah
Journal:  J Inflamm (Lond)       Date:  2013-06-25       Impact factor: 4.981

9.  TNFR1 single nucleotide polymorphisms are not associated with cervical HPV-induced pre-malignant lesion but regulate in situ cervical TNFR1 expression.

Authors:  Natália Pereira da Rocha; Elyzabeth Avvad-Portari; Fábio Russomano; Eric Henrique Roma; Amanda Chaves Pinto; Evandro Klumb; Jacyara Macedo; Ana Teresa Gomes Fernandes; Maria da Glória Bonecini-Almeida
Journal:  Oncotarget       Date:  2019-01-29

Review 10.  TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors.

Authors:  Yuqiao Sheng; Feng Li; Zhihai Qin
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.